BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Bick J, Culbert G, Al-Darraji HA, Koh C, Pillai V, Kamarulzaman A, Altice F. Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia. Int J Prison Health 2016;12:253-69. [PMID: 27921633 DOI: 10.1108/IJPH-06-2016-0017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
2 Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 2016;12:721-31. [DOI: 10.1080/17425255.2016.1183644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
3 Foschi FG, Borghi A, Grassi A, Lanzi A, Speranza E, Vignoli T, Napoli L, Olivoni D, Sanza M, Polidori E, Greco G, Bassi P, Cristini F, Ballardini G, Altini M, Conti F, On Behalf Of Mith Group. Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs. J Clin Med 2021;10:4001. [PMID: 34501448 DOI: 10.3390/jcm10174001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lunn RM, Jahnke GD, Rabkin CS. Tumour virus epidemiology. Philos Trans R Soc Lond B Biol Sci 2017;372:20160266. [PMID: 28893933 DOI: 10.1098/rstb.2016.0266] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
5 Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Reference Citation Analysis]
6 Murdock RM, Brizzi MB, Perez O, Badowski ME. Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review. Infect Dis Ther 2019;8:23-32. [PMID: 30607808 DOI: 10.1007/s40121-018-0228-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Pereson MJ, Martínez AP, Isaac K, Laham G, Ridruejo E, Garcia GH, Flichman DM, Di Lello FA. Seroprevalence of hepatitis B, hepatitis C and HIV infection among patients undergoing haemodialysis in Buenos Aires, Argentina. J Med Microbiol 2021;70. [PMID: 33180017 DOI: 10.1099/jmm.0.001278] [Reference Citation Analysis]
9 Daw MA, El-Bouzedi A, Ahmed MO, Dau AA, Agnan MM; In association with the Libyan Study Group of Hepatitis & amp; HIV. Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa. Travel Med Infect Dis. 2016;14:517-526. [PMID: 27502972 DOI: 10.1016/j.tmaid.2016.05.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
10 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chouikha A, Ghrabi A, Ghodbane A, Hammemi W, Khedhiri M, Sadraoui A, Touzi H, Hassine HB, Maatoug S, Bensaoud C, Abdelhak S, Bouarrouj S, Gdoura M, Chaouachi H, Triki H. Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal. Front Microbiol 2021;12:697859. [PMID: 34385988 DOI: 10.3389/fmicb.2021.697859] [Reference Citation Analysis]
12 Mehrabi Y, Etemad K, Noroozi A, Higgs P, Nasirian M, Sharhani A, Khademi N, Hajebi A, Noroozi M, Shakiba E, Hamzeh B, Azizmohammad Looha M. Correlates of injecting paraphernalia sharing among male drug injectors in Kermanshah, Iran: implications for HCV prevention. Journal of Substance Use 2020;25:330-5. [DOI: 10.1080/14659891.2019.1698670] [Reference Citation Analysis]
13 Al-Busafi SA, Al-Shuaili H, Omar H, Al-Zuhaibi H, Jeyaseelan L, Al-Naamani K. Epidemiology of Chronic Hepatitis C Infections at a Tertiary Care Centre in Oman. Sultan Qaboos Univ Med J 2017;17:e404-10. [PMID: 29372081 DOI: 10.18295/squmj.2017.17.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Liu C, Ma YL, Liu XH, Duan YR, Liu PL, Wang X, Yin P. Sociodemographic Factors Associated With HIV/HCV High-Risk Behaviors Among People Who Use Drugs on Methadone Maintenance Treatment: A 10-Year Observational Study. Front Psychiatry 2021;12:707257. [PMID: 34594250 DOI: 10.3389/fpsyt.2021.707257] [Reference Citation Analysis]
15 Sharhani A, Mehrabi Y, Noroozi A, Nasirian M, Higgs P, Hajebi A, Hamzeh B, Khademi N, Noroozi M, Shakiba E, Etemad K. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.58739] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
16 Akiyama MJ, Muller A, Huang O, Lizcano J, Nyakowa M, Riback L, Ross J, Bundi H, Kulabi ES, Mwangi AM, Musyoki H, Cherutich P, Kurth A. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study. Glob Public Health 2021;:1-13. [PMID: 33689563 DOI: 10.1080/17441692.2021.1896763] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Roncero C, Littlewood R, Vega P, Martinez-Raga J, Torrens M. Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. Eur J Gastroenterol Hepatol 2017;29:629-33. [PMID: 28230562 DOI: 10.1097/MEG.0000000000000855] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
18 Daw MA, El-Bouzedi AA, Ahmed MO, Dau AA, Agnan MM, Drah AM. Geographic integration of hepatitis C virus: A global threat. World J Virol 2016; 5(4): 170-182 [PMID: 27878104 DOI: 10.5501/wjv.v5.i4.170] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
19 Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect 2017;6:e95. [PMID: 29089588 DOI: 10.1038/emi.2017.77] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
20 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
21 Akiyama MJ, Riback L, Reeves JD, Lie YS, Agyemang L, Norton BL, Arnsten JH, Litwin AH. Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens. Open Forum Infect Dis 2021;8:ofab474. [PMID: 34692891 DOI: 10.1093/ofid/ofab474] [Reference Citation Analysis]
22 Sagnelli E, Starace M, Minichini C, Pisaturo M, Macera M, Sagnelli C, Coppola N. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection 2018;46:761-83. [DOI: 10.1007/s15010-018-1188-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
23 Schuermans W, Orlent H, Desombere I, Descheemaeker P, Van Vlierberghe H, Geerts A, Verhelst X, Reynders M, Padalko E. Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form. Int J Mol Sci 2016;17:E1384. [PMID: 27563879 DOI: 10.3390/ijms17091384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
24 Wang X, Wei L. Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. J Clin Transl Hepatol 2021;9:419-27. [PMID: 34221928 DOI: 10.14218/JCTH.2020.00097] [Reference Citation Analysis]
25 Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals: HCV Mutations Versus DAAs. J Med Virol 2016;88:1659-71. [DOI: 10.1002/jmv.24527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
26 Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13. [PMID: 29271117 DOI: 10.1111/apm.12790] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Fichter M, Piradashvili K, Pietrzak-Nguyen A, Pretsch L, Kuhn G, Strand S, Knuf M, Zepp F, Wurm FR, Mailänder V, Landfester K, Gehring S. Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses. Biomaterials 2016;108:1-12. [PMID: 27614817 DOI: 10.1016/j.biomaterials.2016.08.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
28 Chin-Yee B, Subramanian SV, Verma AA, Laupacis A, Razak F. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy. Milbank Q 2018;96:369-401. [PMID: 29870114 DOI: 10.1111/1468-0009.12328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
29 Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, Gentile I, Sogari F, Pierri P, Surace LA, Morisco F, Tundo P, Brancaccio G, Serviddio G, Gatti P, Termite AP, Di Costanzo GG, Caroleo B, Cozzolongo R, Coppola N, Longo A, Fontanella L, Federico A, Rosato V, Terrenato I, Masarone M. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver Int. 2019;39:1852-1859. [PMID: 31175707 DOI: 10.1111/liv.14170] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
30 Arasteh K, Des Jarlais DC, Feelemyer J, Mcknight C. Hepatitis C incidence and prevalence among Puerto Rican people who use drugs in New York City. Global Public Health 2020;15:1789-99. [DOI: 10.1080/17441692.2020.1768276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Donyavi T, Bokharaei-Salim F, Khanaliha K, Sheikh M, Bastani MN, Moradi N, Babaei R, Habib Z, Fakhim A, Esghaei M. High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection. Arch Virol. 2019;164:2493-2504. [PMID: 31346769 DOI: 10.1007/s00705-019-04353-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
32 Sedeño-Monge V, Laguna-Meraz S, Santos-López G, Panduro A, Sosa-Jurado F, Jose-Abrego A, Meléndez-Mena D, Muñoz-Ramírez MA, Cosme-Chávez M, Roman S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008-2019). Ann Hepatol 2021;20:100292. [PMID: 33259949 DOI: 10.1016/j.aohep.2020.100292] [Reference Citation Analysis]
33 Ndjoyi-Mbiguino A, Kombe Kombe AJ, Bivigou-Mboumba B, Zoa-Assoumou S, Akombi FL, Nzengui Nzengui F, M'boyis Kamdem H, François-Souquière S. Low prevalence of HCV infection with predominance of genotype 4 among HIV patients living in Libreville, Gabon. PLoS One 2018;13:e0190529. [PMID: 29385148 DOI: 10.1371/journal.pone.0190529] [Reference Citation Analysis]